ArticleJACC. Case reports2025
Multimodal Cardiac Imaging of a Sudden Cardiac Death Survivor From Central America.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSudden cardiac death (SCD) in a nonimmunosuppressed individual from El Salvador who had visited 2 Trypanosoma cruzi seropositive siblings raised clinical suspicion for Chagas disease. CASE SUMMARY: A 61-year-old male SCD survivor presented with electrocardiogram conduction abnormalities, cardiomegaly, myocardial necrosis with basal inferolateral aneurysm formation (echocardiography, left ventriculography), and sluggish contrast flow in the absence of coronary obstruction. Cardiac magnetic resonance defined the extent of myocardial fibrosis (delayed enhancement) from microvascular disease and guided endomyocardial biopsy. T. cruzi serology studies and circulating inflammatory markers supported late-stage Chagas cardiomyopathy. DISCUSSION: Patients in T. cruzi-endemic regions are at an increased risk of developing Chagas cardiomyopathy, predisposing to SCD. Multimodal imaging provided indications for antiparasitic therapy to reduce disease progression and for dual-chamber implantable cardioverter defibrillator for secondary prevention in high-risk patients (Rassi score = 13). TAKE-HOME MESSAGE: In SCD survivors with Chagas cardiomyopathy, multimodal cardiac imaging: 1) improves early management; 2) guides antiparasitic therapy; and 3) adds prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.